- Trials with a EudraCT protocol (32)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
32 result(s) found for: Acetylcholine Receptor.
Displaying page 1 of 2.
EudraCT Number: 2006-004374-27 | Sponsor Protocol Number: ProPATIent | Start Date*: 2006-10-12 |
Sponsor Name:Philipps-University | ||
Full Title: Prospective, randomized, doubleblind, placebo-controlled trial on changes in acetylcholine receptor antibody titres in autoimmune myasthenia gravis after influenza vaccination (ProPATIent) | ||
Medical condition: Generalized Myasthenia gravis with positive antibodies against Acetylcholine-receptors (ICD10GM2006 G70.0) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-004979-19 | Sponsor Protocol Number: EK Reg.-Nr. 040-2007 | Start Date*: 2009-01-08 |
Sponsor Name:University of Leipzig | ||
Full Title: In-vivo assessment of nicotinic acetylcholine receptor binding in neurodegenerative diseases using the radioligand 2-[18F]FA-85380 and positron emission tomography (PET) | ||
Medical condition: To test a diagnostic imaging tool for specifically assessing the nicotinic acetylcholine receptor in vivo in patients with neurodegenerative diseases | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005433-39 | Sponsor Protocol Number: ADFNLE | Start Date*: 2012-03-22 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI | |||||||||||||
Full Title: PHASE II OPEN STUDY ABOUT THE EFFECTIVENESS OF FENOFIBRATE AS ADD ON THERAPY FOR DRUG RESISTANT NOCTURNAL FRONTAL LOBE EPILEPSY (FNLE) . | |||||||||||||
Medical condition: Drug resistant nocturnal frontal lobe epilepsy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002599-15 | Sponsor Protocol Number: 21709298 | Start Date*: 2017-11-07 | |||||||||||
Sponsor Name:Aarhus University | |||||||||||||
Full Title: Effect of pyridostigmine (Mestinon®) on muscle strength in Myasthenia Gravis. | |||||||||||||
Medical condition: Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016446-50 | Sponsor Protocol Number: - | Start Date*: 2010-04-19 | |||||||||||
Sponsor Name:Maastricht University - CAPHRI School for Public Health and Primary Care | |||||||||||||
Full Title: Helping more smokers to quit by combining varenicline with counselling for smoking cessation. The COVACO randomized controlled trial. | |||||||||||||
Medical condition: Smoking: Subjects must be daily smokers | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002243-27 | Sponsor Protocol Number: 305/2004 | Start Date*: 2004-08-14 |
Sponsor Name:Clinical Pharmacology | ||
Full Title: Vascular effects of peroxisome proliferator–activated receptor gamma stimulation with rosiglitazone during exogenousely elevated free fatty acid concentrations in healthy volunteers | ||
Medical condition: healthy | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-000097-35 | Sponsor Protocol Number: CCFZ533X2204 | Start Date*: 2015-09-02 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multi-center, randomized, double-blind, placebo-controlled, parallel group study to preliminarily evaluate the safety, tolerability, pharmacokinetics and efficacy of CFZ533 in patients with moder... | |||||||||||||
Medical condition: Acquired myasthenia gravis (MG) is an autoimmune disease that leads to fluctuating muscle weakness and fatigue. In the most common cases, muscle weakness is caused by circulating antibodies that bi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002132-25 | Sponsor Protocol Number: ARGX-113-1704 | Start Date*: 2019-04-30 | |||||||||||||||||||||
Sponsor Name:argenx BVBA | |||||||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis Having Generalized Muscle ... | |||||||||||||||||||||||
Medical condition: Myasthenia Gravis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) DK (Completed) FR (Completed) CZ (Completed) DE (Completed) HU (Completed) BE (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-000397-18 | Sponsor Protocol Number: MedOPP341 | Start Date*: 2021-07-30 | ||||||||||||||||
Sponsor Name:MEDICA SCIENTIA INNOVATION RESEARCH S.L. | ||||||||||||||||||
Full Title: A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic CArcinoma PaTIents. PECATI | ||||||||||||||||||
Medical condition: Metastatic Thymic Carcinoma & B3-thymoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000949-14 | Sponsor Protocol Number: VIB0551.P3.S1 | Start Date*: 2020-11-16 | |||||||||||
Sponsor Name:Viela Bio, Inc. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 3 STUDY WITH OPEN-LABEL PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF INEBILIZUMAB IN ADULTS WITH MYASTHENIA GRAVIS | |||||||||||||
Medical condition: Myasthenia Gravis which is either due to acetylcholine receptor antibodies (AChR) or muscle specific kinase antibodies (MuSK). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DK (Prematurely Ended) DE (Trial now transitioned) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001564-30 | Sponsor Protocol Number: RA101495-02.301(RAISE) | Start Date*: 2020-03-31 | |||||||||||
Sponsor Name:Ra Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Generalized Myasthenia Gravis | |||||||||||||
Medical condition: Generalized Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NO (Completed) GB (GB - no longer in EU/EEA) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002623-42 | Sponsor Protocol Number: 66623 | Start Date*: 2019-02-18 | |||||||||||
Sponsor Name:Academic Medical Center | |||||||||||||
Full Title: Vasospastic angina treatment by Endothelin Receptor Antagonism; a proof of concept study | |||||||||||||
Medical condition: Vasospastic angina, i.e. epicardial vasospasm or microvascular coronary dysfunction. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002817-37 | Sponsor Protocol Number: PIX200701 | Start Date*: 2008-07-29 | |||||||||||
Sponsor Name:ISTITUTO NEUROLOGICO "CARLO BESTA" | |||||||||||||
Full Title: A PHASE II, PLACEBO CONTROLLED, DOSE FINDING PILOT STUDY OF PIXANTRONE EFFICACY ADMINISTERED INTRAVENOUSLY IN PATIENTS AFFECTED WITH MYASTHENIA GRAVIS | |||||||||||||
Medical condition: Patients affected with MG showing clinically meaningful improvement after therapeutic plasmapheresis. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024208-81 | Sponsor Protocol Number: CHAMPIXASTHMA | Start Date*: 2011-02-04 | |||||||||||
Sponsor Name:Christian Westergaard | |||||||||||||
Full Title: Smoking young asthmatics: Change of inflammation and quitting cessation rate – effect of Champix | |||||||||||||
Medical condition: Asthma and smoking cessation. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004086-38 | Sponsor Protocol Number: ARGX-113-2002 | Start Date*: 2021-08-06 | |||||||||||
Sponsor Name:argenx BV | |||||||||||||
Full Title: A Long-Term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myast... | |||||||||||||
Medical condition: Generalized Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) HU (Ongoing) BE (Ongoing) NL (Ongoing) IT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005762-34 | Sponsor Protocol Number: MGCDB001 | Start Date*: 2021-07-15 | |||||||||||
Sponsor Name:Medical University of Lublin | |||||||||||||
Full Title: A phase 2 clinical trial assessing the efficacy and safety of adding cladribine for treatment modifying course of seropositive myasthenia gravis | |||||||||||||
Medical condition: Myasthenia gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002133-37 | Sponsor Protocol Number: ARGX-113-1705 | Start Date*: 2019-06-06 | |||||||||||||||||||||
Sponsor Name:argenx BVBA | |||||||||||||||||||||||
Full Title: A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis having Generalized... | |||||||||||||||||||||||
Medical condition: Myasthenia Gravis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) CZ (Completed) DE (Completed) DK (Completed) BE (Completed) HU (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000968-18 | Sponsor Protocol Number: MG0003 | Start Date*: 2019-09-06 | |||||||||||
Sponsor Name:UCB Biopharma SRL | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis. | |||||||||||||
Medical condition: Generalized myasthenia gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) PL (Completed) DE (Completed) HU (Completed) CZ (Completed) BE (Completed) ES (Restarted) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005841-18 | Sponsor Protocol Number: ARGX-113-2006 | Start Date*: 2021-09-29 | |||||||||||
Sponsor Name:argenx BV | |||||||||||||
Full Title: Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis | |||||||||||||
Medical condition: Generalized Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) NL (Ongoing) FR (Ongoing) Outside EU/EEA AT (Ongoing) IT (Ongoing) DE (Ongoing) PL (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002068-26 | Sponsor Protocol Number: BEL115123 | Start Date*: 2011-11-24 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Belimumab in Subjects with Generalized Myasthenia Gravis (MG). | |||||||||||||
Medical condition: Myasthenia Gravis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.